Reporting from AACR 2023, Robin Katie Kelley discusses the phase III KEYNOTE-966 study evaluating the combination of pembrolizumab with gemcitabine and cisplatin versus gem/cis alone in patients with previously untreated advanced biliary tract cancer. Longer overall survival and duration of response validate the role of immune checkpoint inhibition in combination with chemotherapy as first-line treatment option that improves outcomes in these patients.
Abstract: CT008 - Pembrolizumab (pembro) in combination with gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC): Phase 3 KEYNOTE-966 study
Simultaneously published in The Lancet